Lantern Pharma Inc To Host Synthetic Lethality KOL Webinar Transcript
Good afternoon, everyone. I'm Nicole Leber with Investor Relations at Lantern Pharma, and welcome to Lantern's key opinion leader webinar on synthetic lethality, the unique and powerful mechanism of action behind Lantern's drug candidates, LP-184, LP-284, and LP-100.
In oncology drug development, synthetic lethality has become a highly desired capability for small molecules as it promotes the selective anti-tumor toxicity of cancer cells while reducing potential side effects to normal cells. This mechanism of action can exploit vulnerabilities in cancer cells known as DNA damage repair deficiencies, which are common in 25% to 30% of solid tumors.
Using synthetic lethality, Lantern's drug candidate, LP-184, has demonstrated nanomolar potency across a comprehensive number of in vitro and in vivo preclinical models in solid tumors as well as adult and pediatric central nervous system cancers. Based on its synthetic lethality mechanism of action and strong preclinical results, Lantern is targeting advancing LP-184 to a first-in-human Phase 1 clinical
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
